Rituximab Restores IFN-γ-STAT1 Function and Ameliorates Disseminated Mycobacterium avium Infection in a Patient with Anti-Interferon-γ Autoantibody.
J Clin Immunol
; 37(7): 644-649, 2017 Oct.
Article
en En
| MEDLINE
| ID: mdl-28779413
ABSTRACT
A 67-year-old Japanese female with back pain and severe cachexia visited our hospital. The diagnosis was disseminated Mycobacterium avium complex infection (dMAC) with multiple bone involvement. Anti-mycobacterial chemotherapy was started, but fever persisted and dislocation of cervical vertebrae has made her bedridden. Because anti-interferon (IFN)-γ autoantibody was positive, four doses of rituximab 375 mg/m2, every 7 day, were administered. Soon after treatment, progression of osteolytic lesions and wasting has stopped. We proved that rituximab has recovered IFN-γ signaling as shown by IFN-γ-induced STAT1 phosphorylation. It can be a promising option for dMAC cases with anti-IFN-γ autoantibody.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Autoanticuerpos
/
Infección por Mycobacterium avium-intracellulare
/
Interferón gamma
/
Rituximab
/
Factores Inmunológicos
Límite:
Aged
/
Female
/
Humans
Idioma:
En
Revista:
J Clin Immunol
Año:
2017
Tipo del documento:
Article
País de afiliación:
Japón